David Margel
Papers
1
Total Citations
37
H-Index
1
About
David Margel is a leading urologic oncologist whose research focuses on advancing the diagnosis and treatment of prostate cancer, with a particular emphasis on integrating novel radionuclide therapies into clinical practice. His most impactful work, a single-arm Phase 1 trial published in 2022, pioneered the use of neoadjuvant 177Lu-PSMA-I&T radionuclide treatment in high-risk prostate cancer patients prior to radical prostatectomy. This landmark study, which has already garnered 37 citations, demonstrated the feasibility and safety of combining targeted molecular radiotherapy with surgery, opening a new frontier in personalized, multimodal cancer care. Margel’s contributions extend beyond this trial; he has been instrumental in refining PSMA-based imaging and therapeutic strategies, helping to bridge the gap between experimental nuclear medicine and standard surgical oncology. His work is widely recognized for its translational impact, directly influencing treatment protocols for aggressive prostate cancer. With a growing citation record and a reputation for rigorous clinical investigation, Margel continues to shape the future of urologic oncology, offering patients more precise, less invasive options in the fight against high-risk disease.
Research Focus
Key Achievements
Top Papers
- 1